EOLS - NASDAQ

Evolus, Inc.

Evolus, Inc.

EOLS·NASDAQ

$6.03

-2.3%
HealthcareDrug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$397.10M
EPS-0.8000
P/E Ratio-7.54
Earnings Date08/04/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Evolus, Inc.

Evolus, Inc. Earnings Call Transcripts

EOLS · NASDAQ

Related Guides

Blog Categories

Continue your EOLS research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.